Lexaria Updates Progress on Human Study #7 lexariabioscience.com/2026/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - Amycretin and retatrutide to be tested for compatibility with DehydraTECH lexariabioscience.com/2026/0… #Biotech #DrugDelivery #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria to Begin New Human Clinical Study in GLP-1 - Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) lexariabioscience.com/2026/0… #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria’s Robust Patent Portfolio Continues to Grow - Lexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugs lexariabioscience.com/2026/0…

Major drug makers are in a global race — not just to create the next breakthrough weight-loss pill, but to make it safer. That’s where @LexariaBioCorp stands out. In a recent clinical study, the company’s patented oral delivery technology cut adverse events by up to 50% — a meaningful step toward more tolerable, next-gen weight-management drugs. Instead of building a single therapy, Lexaria is developing a platform: a technology that enhances absorption and may improve how future oral medications behave in the body, without changing the drug itself. As demand surges for safer, effective metabolic treatments, Lexaria is positioning its technology as a potential upgrade layer for an entire class of next-generation therapies. Lexaria Bioscience — advancing better delivery for the medicines of tomorrow. Learn More: b-tv.com/post/lexaria-biosci…

The race is on: major drug companies are competing to develop next-generation oral weight-loss drugs — but effectiveness isn’t enough. Safety and tolerability remain key hurdles. @LexariaBioCorp is tackling the challenge differently. Its patented oral delivery technology improves absorption, helping reduce adverse events by up to 50% in clinical testing. By enhancing how drugs enter the body, rather than altering the active ingredient, Lexaria is unlocking a major opportunity in a multi-billion-dollar market — improving patient experience and long-term adherence. In a rapidly expanding weight-management market, delivery technology may be the missing piece for next-generation oral therapies. Lexaria Bioscience — changing how medicines are delivered, one breakthrough at a time. Learn More: b-tv.com/post/lexaria-biosci…

Lexaria Announces New R&D Plans for 2026 - Exciting new human and animal studies designed to enhance business opportunities lexariabioscience.com/2026/0… $LEXX #Biotech #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Announces Positive Final Results From Human Pilot Study #5 lexariabioscience.com/2026/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Awarded Six Additional Patents - Lexaria now has 60 patents granted around much of the world lexariabioscience.com/2026/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Releases Annual Letter from the CEO lexariabioscience.com/2026/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 lexariabioscience.com/2025/1… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 lexariabioscience.com/2025/1… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended lexariabioscience.com/2025/1… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Bioscience Corp. Provides Strategic Update lexariabioscience.com/2025/1… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria’s Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain lexariabioscience.com/2025/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria’s Phase 1b GLP-1 Study Achieves Important “Last Patient Last Visit” Milestone lexariabioscience.com/2025/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

GLP-1 “Arms Race” Broadens to Include Dozens of Companies - Lexaria highlights DehydraTECH’s adverse events improvement opportunity lexariabioscience.com/2025/0… $LEXX #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b Study lexariabioscience.com/2025/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria’s DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry lexariabioscience.com/2025/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Reaches Patent Milestone – 50 Patents Now Granted Worldwide!! lexariabioscience.com/2025/0… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #patent